ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
August 01 2017 - 9:00AM
Business Wire
ACADIA to Host Conference Call and Webcast on
Tuesday, August 8, 2017, at 5:00 p.m. Eastern Time
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in central
nervous system disorders, today announced that it will report its
financial results for the second quarter ended June 30, 2017 on
Tuesday, August 8, 2017, after the U.S. financial markets close.
ACADIA's management will host a conference call and webcast on
Tuesday, August 8, 2017, at 5:00 p.m. Eastern Time to discuss
ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 for
participants in the United States or Canada and 830-865-2550 for
international callers (reference passcode 12799639). A telephone
replay of the conference call may be accessed through August 22,
2017 by dialing 855-859-2056 for callers in the United States or
Canada and 404-537-3406 for international callers (reference
passcode 12799639). The conference call also will be webcast live
on ACADIA’s website, www.acadia-pharm.com under the investors
section and will be archived there until August 22, 2017.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines that address unmet
medical needs in central nervous system disorders. ACADIA maintains
a website at www.acadia-pharm.com to which we regularly post copies
of our press releases as well as additional information and through
which interested parties can subscribe to receive e-mail
alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
progress and timing of ACADIA’s drug discovery and development
programs, and the benefits to be derived from NUPLAZID®
(pimavanserin) and ACADIA’s product candidates. These statements
are only predictions based on current information and expectations
and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, approval and
commercialization, and in collaborations with others, and the fact
that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year
ended December 31, 2016 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170801005432/en/
ACADIA Pharmaceuticals Inc.Lisa Barthelemy, Investor
Relations858-558-2871ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024